BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2196459)

  • 1. Adenovirus vaccine strains genetically engineered to express HIV-1 or HBV antigens for use as live recombinant vaccines.
    Hung PP; Chanda PK; Natuk RJ; Mason BB; Chengalvala M; Bhat BM; Molnar-Kimber KL; Dheer SK; Morin JE; Mizutani S
    Nat Immun Cell Growth Regul; 1990; 9(3):160-4. PubMed ID: 2196459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HBV surface antigen or HIV envelope protein using recombinant adenovirus vectors.
    Hung PP; Morin JE; Lubeck MD; Barton JE; Molnar-Kimber KL; Mason BB; Dheer SK; Jarocki-Witek V; Kostek B; Zandle G
    Nat Immun Cell Growth Regul; 1988; 7(3):135-43. PubMed ID: 3173369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus vectored vaccines.
    Natuk RJ; Davis AR; Chanda PK; Lubeck MD; Chengalvala M; Murthy SC; Wade MS; Dheer SK; Bhat BM; Murthy KK
    Dev Biol Stand; 1994; 82():71-7. PubMed ID: 7958485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120.
    Berkower I; Raymond M; Muller J; Spadaccini A; Aberdeen A
    Virology; 2004 Mar; 321(1):75-86. PubMed ID: 15033567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.
    Brand D; Lemiale F; Thibault G; Verrier B; Lebigot S; Roingeard P; Buzelay L; Brunet S; Barin F
    Virology; 2000 Jun; 271(2):350-62. PubMed ID: 10860888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
    Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
    Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
    Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
    Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.
    Borkowsky W; Wara D; Fenton T; McNamara J; Kang M; Mofenson L; McFarland E; Cunningham C; Duliege AM; Francis D; Bryson Y; Burchett S; Spector SA; Frenkel LM; Starr S; Van Dyke R; Jimenez E
    J Infect Dis; 2000 Mar; 181(3):890-6. PubMed ID: 10720509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and analysis of recombinant BCG vector systems.
    Fuerst TR; de la Cruz VF; Bansal GP; Stover CK
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1451-5. PubMed ID: 1466980
    [No Abstract]   [Full Text] [Related]  

  • 10. Human CD4+ T cells can discriminate the molecular and structural context of T epitopes of HIV gp120 and HIV p66.
    Manca F; Fenoglio D; Valle MT; Li Pira G; Kunkl A; Ferraris A; Saverino D; Lancia F; Mortara L; Lozzi L
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):227-37. PubMed ID: 7540488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
    Raz R; Koren R; Bass D
    Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
    Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
    Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Construction and immune potency of recombinant adenovirus containing codon-modified HIV-1 gp120].
    Feng X; Yu SQ; Chen GM; Zuo JM; Zhou L; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Jun; 18(2):113-7. PubMed ID: 15340495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
    Yue Q; Hu X; Yin W; Xu X; Wei S; Lei Y; Lü X; Yang J; Su M; Xu Z; Hao X
    J Virol Methods; 2007 Apr; 141(1):41-8. PubMed ID: 17197041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for the use of synthetic antigens in immunodiagnosis.
    Khaitov RM; Andreev SM
    Biomed Sci; 1990; 1(6):553-64. PubMed ID: 1722715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Western blot analysis of the reactivity between envelope proteins of hepatitis B viruses from Brazilian carriers and antibodies raised against recombinant hepatitis B vaccines.
    De Castro L; Yoshida CF; Gaspar AM; Gomes SA
    Acta Virol; 1996; 40(5-6):251-8. PubMed ID: 9171452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
    Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
    J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.